1. Andine P, Lehmann A, Ellren K et al (1988) The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neurosci Lett 90:208–212
2. Badawy AAB, Dougherty DM (2016) Assessment of the human kynurenine pathway: comparisons and clinical implications of ethnic and gender differences in plasma tryptophan, kynurenine metabolites, and enzyme expressions at baseline and after acute tryptophan loading and depletion. Int J Tryptophan Res 9:31–49
3. Baran H, Hainfellner JA, Kepplinger B, Mazal PR, Schmid H, Budka H (2000) Kynurenic acid metabolism in the brain of HIV-1 infected patients. J Neural Transm 107(10):1127–1138
4. Boasso A, Shearer GM (2007) How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr Drug Metab 8:217–223
5. Bracchi M, Pagani N, Clarke A, Adams T, Waters L, Bolton M, et al (n.d.) Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system toxicity. International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK, p 209